Previous close | 0.0500 |
Open | 0.0500 |
Bid | 0.0000 |
Ask | 0.0000 |
Strike | 115.00 |
Expiry date | 2024-06-21 |
Day's range | 0.0500 - 0.0900 |
Contract range | N/A |
Volume | |
Open interest | N/A |
With the growing influence of GenAI in the MedTech sector, innovators like ZBH, GEHC and MDT are poised to thrive.
Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that Devdatt "Dev" Kurdikar, President, Chief Executive Officer and a member of the board of directors of Embecta Corp. (embecta), has been appointed to the Zimmer Biomet Board, effective immediately. embecta (Nasdaq: EMBC), formerly part of Becton, Dickinson and Company (BD), is one of the largest pure-play diabetes management companies in the world.
The board of Zimmer Biomet Holdings, Inc. ( NYSE:ZBH ) has announced that it will pay a dividend of $0.24 per share on...